MedPath

Investigating the effect of 12 weeks of HIFT and Ginkgo biloba consumption on serum levels of inflammatory indicators and antioxidant defense

Not Applicable
Recruiting
Conditions
--
Inflammatory status and antioxidant defense.
Registration Number
IRCT20230919059465N1
Lead Sponsor
Islamic Azad University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
48
Inclusion Criteria

All firefighters who are in the operational line, have more than 3 years of work experience, age range of 25 to 50 years, not suffering from specific physiological and metabolic diseases, not taking special dietary and sports supplements.

Exclusion Criteria

Work experience of less than 3 years, age less than 25 years and more than 50 years, suffering from a disabling disease from participating in training, taking special dietary and sports supplements

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ipocalin-2. Timepoint: Two stages: before the start of the study and after the end of 12 weeks of interference. Method of measurement: Valid and standard lipocalin-2 laboratory kit.;Interleukin-8 (IL-8). Timepoint: Two stages: before the start of the study and after the end of 12 weeks of intervention. Method of measurement: Valid and standard IL-8 laboratory kit.;Interleukin-1beta (IL-1ß). Timepoint: Two stages: before the start of the study and after the end of 12 weeks of intervention. Method of measurement: Valid and standard IL-1ß laboratory kit.;Superoxide desmutase (SOD). Timepoint: Two stages: before the start of the study and after the end of 12 weeks of intervention. Method of measurement: Valid and standard SOD laboratory kit.;Catalase (CAT). Timepoint: Two stages: before the start of the study and after the end of 12 weeks of intervention. Method of measurement: Valid and standard CAT laboratory kit.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath